Novo Nordisk A/S (NYSE:NVO)
| 136.74 Delayed Data As of 3:59pm ET |  +4.40 / +3.32%Today’s Change | 94.75 Today|||52-Week Range 144.78 | +1.03% Year-to-Date |
Latest NVO News | Press Releases
Today’s Trading
| Previous close | 132.34 |
| Today’s open | 135.67 |
| Day’s range | 135.26 - 137.42 |
| Volume | 1,745,381 |
| Average volume (3 months) | 1,397,545 |
| Market cap | $236.1B |
Data as of 3:59pm ET, 02/03/2023
Growth & Valuation
| Earnings growth (last year) | +19.70% |
| Earnings growth (this year) | +11.37% |
| Earnings growth (next 5 years) | +14.00% |
| Revenue growth (last year) | +15.27% |
| P/E ratio | 38.6 |
| Price/Sales | 11.53 |
| Price/Book | 29.10 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| PFEPfizer | -0.29 | -0.64% |
| ABBVAbbVie | +0.43 | +0.30% |
| MRKMerck | -0.52 | -0.51% |
| AZNAstraZeneca | +0.31 | +0.49% |
Data as of 4:00pm ET, 02/03/2023
Financials
| Next reporting date | May 4, 2023 |
| EPS forecast (this quarter) | $1.07 |
| Annual revenue (last year) | $22.4B |
| Annual profit (last year) | $7.6B |
| Net profit margin | 33.92% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Bagsværd, Capital Region |
Forecasts
